Subsequent Development
Pfizer, after the CETP agent torcetrapib failed in a large human safety trial, decided to exit the cardiovascular market in 2008, though they continue to market Lipitor aggressively.
Esperion, divested by Pfizer in 2008, is back in business and continue to work on HDL mimetic therapies. The company established an agreement with TransGenRx as a protein source.
Calgary-based SemBioSys Genetics Inc. was a biotechnology company that was using Safflower to develop commercial quantities of ApoA-1 Milano. On October 11, 2011 SemBioSys Genetics signed a multi-product commercialization and platform collaboration agreement with Tasly Pharmaceuticals of Tianjin China. In May 2012, SemBioSys terminated its operations and announced that Tasly had terminated their agreement.
On 22 December 2009 The Medicines Company announced it had entered into an exclusive worldwide licensing agreement with Pfizer Inc. for ApoA-I Milano which it then renamed MDCO-216.
On the 12th of July 2010 The Medicines Company signed a pharmaceutical development and manufacturing contract with OctoPlus (Netherlands-based drug delivery and drug development company) to perform process development and clinical manufacturing of MDCO-216. The Medicines Company expects to commence clinical studies sometime in 2011.
Cardigant Medical is a Los Angeles based biotech company currently working to commercialize ApoA-1 Milano to treat various vascular diseases.
Read more about this topic: Apo A-1 Milano
Famous quotes containing the words subsequent and/or development:
“Reading ... is an activity subsequent to writing: more resigned, more civil, more intellectual.”
—Jorge Luis Borges (1899–1986)
“Other nations have tried to check ... the fulfillment of our manifest destiny to overspread the continent allotted by Providence for the free development of our yearly multiplying millions.”
—John Louis O’Sullivan (1813–1895)